Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Microfluidic chip technology integrates basic operational units such as sample preparation, reaction, analysis, and detection, harnessing techniques from the fields of chemistry and biology into a chip of several square centimeters, automatically completing the entire analysis process.

Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its liquid biopsy-based ExoDx Prostate IntelliScore (EPI) test in the state.

Beckman Coulter Life Sciences said today it has acquired single-cell data analysis and software-as-a-service company Cytobank for an undisclosed amount.

Resolution Bioscience is the latest in a long line of firms that has been granted breakthrough device designation from FDA. The Kirkland, WA-based company received the designation for its qualitative in vitro diagnostic.

A breach of Quest Diagnostics’ billing collections vendor could have exposed the personal, financial, and medical information of as many as 12 million customers, multiple media outlets are reporting.

There’s a new player in the liquid biopsy field. Thrive Earlier Detection Corp., announced late last month that it has launched and has raised $110 million in its Series A round.

Inivata has developed the InVision platform based on research from the Cancer Research UK Cambridge Institute at the University of Cambridge. Its lead product, InVisionFirst-Lung, is commercially available and was developed to provide molecu

The latest bit of activity comes from Saga Diagnostics, a Lund, Sweden based company that has raised $4.1 million in a financing round. In a release the company said Hadean Ventures, a Nordic focused European life science fund manager, leads

Liquid biopsy has attracted a surge of companies that are trying to change the way cancer is detected and monitored. But the benefits of this new type of technology can - and should - seep into other disease categories.

Upon closing of the transaction, Burlington, the MA-based company will be a subsidiary of Bracco Imaging, led by its current leadership team. Milan, Italy-based Bracco Imaging said Blue Earth Diagnostics will retain the well-established bran

The San Francisco-based company said it signed a definitive agreement to acquire Singular Bio for $55 million. Singular Bio specializes in developing single molecule detection technology that enables lower costs and expanded use of high-qual